The role of DLL1 in long-term vascular normalization and cancer immunotherapy
The role of DLL1 in long-term vascular normalization and cancer immunotherapy
复制标题
DOI：
10.20892/j.issn.2095-3941.2021.0507
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Huang Yuhui
中科院分区：
文献类型：
--
作者：
Wu Qiaozhen;Huang Yuhui
Cancer immunotherapy, especially immune checkpoint blockade therapy (ICB), has revolutionized cancer treatment, providing a potential curable modality for advanced cancer patients. In immunogenic cancer, such as melanoma and lung cancers with a history of smoking, approximately 30% patients with anti-programmed death 1 (PD1) monotherapy survive more than 5 years. However, despite being a major breakthrough in the treatment of cancer, the majority of cancer patients have not yet benefited from ICB monotherapy1. Thus, innovative strategies to improve ICB efficacy are still needed.
